Download PDF
Erfahrungsheilkunde 2017; 66(04): 208-214
DOI: 10.1055/s-0043-116628
Wissen
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Weißdorn – neue Erkenntnisse zu einer alten Heilpflanze – ein Multitalent für Herz und Kreislauf

Peter W. Gündling
Further Information

Publication History

Publication Date:
05 September 2017 (online)

    Permissions and Reprints

Zusammenfassung

Weißdornextrakte werden seit langem und weltweit zur Behandlung von Herz-Kreislauf-Krankheiten angewendet. In den letzten Jahren wurden klinische Untersuchungen von weit mehr als 4000 Patienten sowie eine Vielzahl an Grundlagenforschungen durchgeführt, die immer wieder neue und überraschende Ergebnisse liefern. Aus Sicht der Naturheilkunde kann Weißdorn daher als ideale Basismedikation sowohl therapeutisch beim Altersherz, beginnender Herzinsuffizienz, endothelialer Dysfunktion, Arteriosklerose und koronarer Herzkrankheit als auch prophylaktisch zur Vermeidung dieser Störungen gelten.

Abstract

Hawthorn extracts have been used worldwide for the treatment of cardiovascular diseases for a long time. In recent years, clinical studies with far more than 4000 patients as well as basic research activities repeatedly showed new and surprising results. From the point of view of naturopathy, hawthorn can therefore be regarded as an ideal basic medication for the treatment of age-related weak heart, beginning cardiac insufficiency, endothelial dysfunction, arteriosclerosis and coronary heart disease as well as for the prevention of these disorders.

Schlüsselwörter

Phytotherapie - Weißdorn - Herzinsuffizienz

Key words

Phytotherapy - hawthorn - heart failure
 

  • Literatur

  • 1 Nationale Versorgungsleitlinie Chronische Herzinsuffizienz, Version 1.4 vom Mai 2011.
    PubMedGoogle Scholar
  • 2 Gündling PW. Brennpunkt Herz. Natürlich heilen und vorbeugen bei Herz-Kreislauf-Problemen. 1. Aufl.. Baden-Baden: Aurelia; 2004
    Google Scholar
  • 3 Gündling PW. Herz- und Gefäßschutz – Was leisten nichtmedikamentöse Maßnahmen?. Der Allgemeinarzt 2007; 29 (02) 6-9
    PubMedGoogle Scholar
  • 4 Gündling PW, Mesenholl-Strehler E. Application and subjective benefit of Crataegus extracts in patients with incipient heart failure with regard to performance and quality of life – a qualitative study. Eur J Integr Med 2009; 1 (04) 238-239
    PubMedGoogle Scholar
  • 5 Gündling PW. Phytotherapie bei Herz-Kreislauf-Krankheiten. Arzt, Zahnarzt & Naturheilverfahren 2010; (01) 5-9
    PubMedGoogle Scholar
  • 6 Gündling PW. Chancen der Ernährungstherapie bei Herzinsuffizienz. Erfahrungsheilkunde 2012; 61 (03) 154-159
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Alehagen U, Aaseth J, Johansson P. Reduced cardiovascular mortality 10 years after supplementation with selenium and coenzyme Q10 for four years: follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly citizens. PLoS ONE. 2015 10. (12): e0141641. doi:10.1371/journal.pone.0141641
    PubMedGoogle Scholar
  • 8 Koch E, Malek FA. Standardized extracts from hawthorn leaves and flowers in the treatment of cardiovascular disorders--preclinical and clinical studies. Planta Med 2011; 77 (11) 1123-1128
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Monographie der Kommission E zu Crataegi cum flore. Bundesanzeiger Nr. 133, 19. Juli 1994.
    PubMedGoogle Scholar
  • 10 Waimer F, Stumpf H. Qualität quantifizierter Pflanzenextrakte. Deutsche Apotheker Zeitung 2006; 146: 1842-1847
    PubMedGoogle Scholar
  • 11 Brixius K, Frank K, Münch G. et al. WS 1442 (Crataegus-Extrakt) wirkt am insuffizienten menschlichen Myokard kontraktionskraftsteigernd. Herz/Kreislauf 1998; 30: 28-33
    PubMedGoogle Scholar
  • 12 Schwinger RH, Pietsch M, Frank K. et al. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol 2000; 35 (05) 700-707
    CrossrefPubMedGoogle Scholar
  • 13 Tauchert M, Ploch M, Hübner WD. Wirksamkeit des Weißdorn-Extraktes Li 132 im Vergleich zu Captopril. Multizentrische Doppelblind-Studie bei 132 Patienten mit Herzinsuffizienz im Stadium II nach NYHA. Münch Med Wochenschr 1994; 136 (Suppl. 01) 27-33
    PubMedGoogle Scholar
  • 14 Eggeling T, Regitz-Zagrosek V, Zimmermann A. et al. Baseline severity but not gender modulates quantified Crataegus extract effects in early heart failure, a pooled analysis of clinical trials. Phytomedicine 2011; 18 (14) 1214-1219
    CrossrefPubMedGoogle Scholar
  • 15 Pittler MH, Guo R, Ernst E. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev. 2008 (1):CD005312
    PubMedGoogle Scholar
  • 16 Wegener T. Weißdorn Extrakt – Aktuelle Erkenntnisse zum Wirkprinzip. Phytokompass 2016; 5: 20-23
    PubMedGoogle Scholar
  • 17 Idris-Khodja N, Auger C, Koch E. et al. Crataegus special extract WS®1442 prevents aging-related endothelial dysfunction. Phytomedicine 2012; 19 (08) –9 699-706
    CrossrefPubMedGoogle Scholar
  • 18 Koch E, Chatterjee SS. Crataegus extract WS-1442 enhances coronary flow in the isolated rat heart by endothelial release of nitric oxide. Naunyn-Schmiedeberg’s Arch Pharmacol 2000; 361 R48
    PubMedGoogle Scholar
  • 19 Brixius K, Willms S, Napp A. et al. Crataegus special extract WS 1442 induces an endothelium-dependent, NO-mediated vasorelaxation via eNOS-phosphorylation at serine 1177. Cardiovasc Drugs Ther 2006; 20 (03) 177-184
    CrossrefPubMedGoogle Scholar
  • 20 Fuchs S, Bischoff I, Willer EA. et al. The dual edema-preventing molecular mechanism of the Crataegus Extract WS 1442 can be assigned to distinct phytochemical fractions. Planta Med 2017; 83 (08) 701-709
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Fischer M, Baessler A, Hense HW. et al. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 2003; 24: 320-328
    PubMedGoogle Scholar
  • 22 Ribeiro TP, Schini-Kerth V. et al. Intake of a standardized Crataegus extract prevents DOCA-salt-induced hypertension, and alteration of cardiac, vascular and renal structure and function in rats: role of oxidative stress. DGK-Kongress; Mannheim: April 2015. P1828(12)
    CrossrefGoogle Scholar
  • 23 Koch E, Spörl-Aich G. Oral treatment with the Crataegus special extract WS® 1442 inhibits cardiac hypertrophy in rats with DOCA-salt or aortic banding induced hypertension. Planta Med 2006; 72 – P_265; DOI: 10.1055/s-2006–950065
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Kraft S, Scheyhing U, Xia N. et al. Der Crataegusextrakt WS® 1442 verändert die Expression von microRNAs in der Mausaorta: Mögliche Bedeutung für die Therapie von Herzerkrankungen. ZPT 2016; 37 (Suppl. 01) S45
    PubMedGoogle Scholar
  • 25 Härtel S. et al. Effects of endurance exercise training and Crataegus extract WS 1442 in patients with heart failure with preserved ejection fraction – a randomized controlled trial. Sports 2014; 2 (03) 59-75
    CrossrefPubMedGoogle Scholar
  • 26 Veveris M, Koch E, Chatterjee SS. Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion. Life Sci 2004; 74 (15) 1945-1955
    CrossrefPubMedGoogle Scholar
  • 27 Schade D. A phytomedicine approach to stem cell modulation for heart regeneration. Planta Med 2015; 81 – SL2B_03; DOI: 10.1055/s-0035–1565303
    PubMedGoogle Scholar
  • 28 Holubarsch CJ. et al. Survival and prognosis: investigation of Crataegus extract WS 1442 in CHF (SPICE) trial study group. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail 2008; 10 (12) 1255-1263
    CrossrefPubMedGoogle Scholar